FCMI
JNCE

Foresite Capital Management III’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Foresite Capital Management III’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-91,600
Closed -$2.01M – 32
2017
Q1 		$2.01M Buy
+91,600
New +$1.94M 0.77% 20

Other funds holding JNCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foresite Capital Management III's JNCE Position: Q2 2017 in Review

Foresite Capital Management III sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2017, closing a stake of 91,600 shares — an estimated $2.01M sold.

Foresite Capital Management III first reported a position in JNCE in Q1 2017 and held it in 1 quarter. The position peaked at $2.01M in Q1 2017. 72 funds tracked by Wall St. Rank hold JNCE as of Q2 2017.

  • Foresite Capital Management III reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 91,600 Jounce Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $2.01M.
  • Foresite Capital Management III first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Foresite Capital Management III's Jounce Therapeutics, Inc. Common Stock position peaked at $2.01M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Foresite Capital Management III's 13F filing for Q2 2017, filed 14 Aug 2017.